[go: up one dir, main page]

UA86924C2 - Лекарственная форма, которая включает мелатонин, для краткосрочного усиления снотворного эффекта снотворных средств, которые не относятся к барбитуратам и производным бензодиазепина - Google Patents

Лекарственная форма, которая включает мелатонин, для краткосрочного усиления снотворного эффекта снотворных средств, которые не относятся к барбитуратам и производным бензодиазепина

Info

Publication number
UA86924C2
UA86924C2 UA20041008558A UA20041008558A UA86924C2 UA 86924 C2 UA86924 C2 UA 86924C2 UA 20041008558 A UA20041008558 A UA 20041008558A UA 20041008558 A UA20041008558 A UA 20041008558A UA 86924 C2 UA86924 C2 UA 86924C2
Authority
UA
Ukraine
Prior art keywords
melatonin
barbiturate
term potentiation
short term
intended
Prior art date
Application number
UA20041008558A
Other languages
English (en)
Ukrainian (uk)
Inventor
Нава Зисапель
Original Assignee
Ньюрим Фармасьютикалз (1991) Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA86924(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ньюрим Фармасьютикалз (1991) Лтд. filed Critical Ньюрим Фармасьютикалз (1991) Лтд.
Publication of UA86924C2 publication Critical patent/UA86924C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Изобретение касается использования мелатонина в производстве лекарственного средства обычного высвобождения или пролонгированного высвобождения для краткосрочного усиления снотворного эффекта на человеческий организм, по крайней мере, одного соединения, выбранного из группы снотворных средств, которые не являются барбитуратами или производными бензодиазепина, и являются модуляторами рецептора ГАМК-А, при условии, что такое лекарственное средство обычного высвобождения содержит количество мелатонина, достаточное для усиления снотворного эффекта указанного, по крайней мере, одного соединения при применении указанного, по крайней мере, одного соединения в таком количестве, что, если бы оно применялось к человеку при отсутствии мелатонина, было бы субтерапевтическим количеством.
UA20041008558A 2002-04-28 2003-03-20 Лекарственная форма, которая включает мелатонин, для краткосрочного усиления снотворного эффекта снотворных средств, которые не относятся к барбитуратам и производным бензодиазепина UA86924C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL149377A IL149377A (en) 2002-04-28 2002-04-28 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds

Publications (1)

Publication Number Publication Date
UA86924C2 true UA86924C2 (ru) 2009-06-10

Family

ID=29227410

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041008558A UA86924C2 (ru) 2002-04-28 2003-03-20 Лекарственная форма, которая включает мелатонин, для краткосрочного усиления снотворного эффекта снотворных средств, которые не относятся к барбитуратам и производным бензодиазепина

Country Status (29)

Country Link
US (1) US20050175692A1 (ru)
EP (1) EP1494650B1 (ru)
JP (1) JP2005527583A (ru)
KR (1) KR101000624B1 (ru)
CN (1) CN100386070C (ru)
AR (1) AR039232A1 (ru)
AT (1) ATE507831T1 (ru)
AU (1) AU2003227304B2 (ru)
BR (1) BR0308762A (ru)
CA (1) CA2477516C (ru)
DE (1) DE60336999D1 (ru)
DK (1) DK1494650T3 (ru)
EA (1) EA007954B1 (ru)
ES (1) ES2366116T3 (ru)
GT (1) GT200300064A (ru)
HN (1) HN2003000115A (ru)
IL (1) IL149377A (ru)
IS (1) IS2858B (ru)
MX (1) MXPA04009893A (ru)
NO (1) NO332525B1 (ru)
NZ (1) NZ536298A (ru)
PE (1) PE20040161A1 (ru)
PL (1) PL209922B1 (ru)
PT (1) PT1494650E (ru)
TW (1) TW200305404A (ru)
UA (1) UA86924C2 (ru)
UY (1) UY27753A1 (ru)
WO (1) WO2003086352A1 (ru)
ZA (1) ZA200407563B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
CN102018681A (zh) * 2010-12-10 2011-04-20 荣港生技医药科技（北京）有限公司 一种美乐托宁缓释剂、其制备方法及其应用
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
EP2570126B1 (en) * 2011-09-16 2014-03-26 Darius Rassoulian Use of melatonin for treating acute alcohol intoxication
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
RS61024B1 (sr) * 2016-10-31 2020-12-31 Neurim Pharma 1991 Mini-tablete melatonina i postupak za njihovu proizvodnju
CN109364031A (zh) * 2018-10-07 2019-02-22 威海贯标信息科技有限公司 一种盐酸曲唑酮片剂组合物
JP2023510223A (ja) * 2020-01-17 2023-03-13 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 徐放性メラトニンペレットを含む剤形

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
AU695366B2 (en) * 1995-02-01 1998-08-13 Neurim Pharmaceuticals (1991) Ltd. Use of melatonin for treating patients suffering from drug addiction
SK283970B6 (sk) * 1996-03-08 2004-06-08 Takeda Chemical Industries, Ltd. Tricyklické zlúčeniny, spôsob výroby a farmaceutický prípravok ich obsahujúci
WO1997037670A1 (en) * 1996-04-10 1997-10-16 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
AU3716997A (en) * 1996-07-17 1998-02-09 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
AU4060599A (en) * 1998-06-09 1999-12-30 Takeda Chemical Industries Ltd. Pharmaceutical composition for treating or preventing sleep disorders
CN1131030C (zh) * 1999-03-18 2003-12-17 胡秀云 一种由褪黑素和安定制成的调节睡眠的组合物
BR0009200A (pt) * 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compostos e composições para o tratamento dedoenças associada com disfunção imune
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Also Published As

Publication number Publication date
CN1646098A (zh) 2005-07-27
PL372867A1 (en) 2005-08-08
AU2003227304A1 (en) 2003-10-27
AU2003227304B2 (en) 2007-12-06
AR039232A1 (es) 2005-02-09
NZ536298A (en) 2008-09-26
HN2003000115A (es) 2004-04-20
CN100386070C (zh) 2008-05-07
IL149377A0 (en) 2009-02-11
CA2477516C (en) 2012-12-11
ATE507831T1 (de) 2011-05-15
NO332525B1 (no) 2012-10-08
IS7492A (is) 2004-10-07
EP1494650B1 (en) 2011-05-04
IS2858B (is) 2013-12-15
BR0308762A (pt) 2005-01-11
KR20040101406A (ko) 2004-12-02
EP1494650A4 (en) 2006-07-12
TW200305404A (en) 2003-11-01
GT200300064A (es) 2003-11-26
EP1494650A1 (en) 2005-01-12
EA200401331A1 (ru) 2005-04-28
ZA200407563B (en) 2005-11-30
KR101000624B1 (ko) 2010-12-10
PE20040161A1 (es) 2004-03-22
DE60336999D1 (de) 2011-06-16
EA007954B1 (ru) 2007-02-27
CA2477516A1 (en) 2003-10-23
WO2003086352A1 (en) 2003-10-23
IL149377A (en) 2012-10-31
PL209922B1 (pl) 2011-11-30
NO20043576L (no) 2004-12-22
AU2003227304A2 (en) 2005-04-14
ES2366116T3 (es) 2011-10-17
HK1075616A1 (zh) 2005-12-23
JP2005527583A (ja) 2005-09-15
PT1494650E (pt) 2011-08-18
MXPA04009893A (es) 2005-06-17
DK1494650T3 (da) 2011-08-08
UY27753A1 (es) 2003-05-30
US20050175692A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
UA86924C2 (ru) Лекарственная форма, которая включает мелатонин, для краткосрочного усиления снотворного эффекта снотворных средств, которые не относятся к барбитуратам и производным бензодиазепина
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
WO2005120393A3 (en) Implantable device for drug delivery and improved visibility
AU2003245368A1 (en) Delivery system for flowable medicinal or therapeutic substances
WO2004093795A3 (en) Compositions for delivery of drug combinations
AU2003295614A1 (en) Delivery of pharmaceutical agents via the human insulin receptor
IL188774A0 (en) Compositions for delivery of drug combinations
WO2004054542A3 (en) Oral drug delivery system comprising high viscosity liquid carrier materials
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
AU2002302890A1 (en) Hydrodynamically balancing oral drug delivery system with biphasic release
MXPA05001607A (es) Forma galenica para suministro de ingredientes activos dirigido al colon.
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
TW200738238A (en) Combination of a long-acting hypnotic agent and a short-acting hypnotic agent, pharmaceutical composition containing it and its application in therapeutics
ES2189252T3 (es) Composiciones analgesicas que comprenden un antagonista de la colecistoquinina y un opioide.
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
MX2009003660A (es) Farmaco combinado.
WO2002034240A3 (en) Delayed and sustained release formulations and method of use thereof
MA27418A1 (fr) Ensemble de distribution de medicament.
DE60319802D1 (de) Sedierende nicht-benzodiazepin-formulierungen
AU2003275006A1 (en) Aerosol drug delivery system employing formulation pre-heating
GB9811221D0 (en) Bacterial-pheromones and uses therefor